Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 3820768
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BI 3820768 is an investigational bispecific T-cell engager (TcE) developed by Boehringer Ingelheim for the treatment of solid tumors. It is designed to bind simultaneously to Claudin 6 (CLDN6), a tight junction protein frequently overexpressed in specific cancers such as germ cell tumors, ovarian cancer, and endometrial cancer, and the CD3 subunit of the T-cell receptor complex. By bridging these two targets, BI 3820768 facilitates the formation of an immunological synapse, leading to T-cell activation, cytokine release, and the targeted lysis of CLDN6-expressing malignant cells. As of 2024, it is being evaluated in a first-in-human Phase I clinical trial to assess its safety, tolerability, and preliminary efficacy in patients with advanced relapsed or refractory tumors.
- Other names
- CLDN6/CD3 T-cell engagerCLDN6/CD3 bispecific antibody
Beyond the preview
Go deeper on BI 3820768.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 3820768.